Key result
In healthy volunteers, hemostatic alterations induced by rivaroxaban were reversed by PCCs, aPCCs, and rFVIIa, whereas dabigatran effects were only reversed by aPCCs.
Why the study?
Do prothrombin complex concentrates (PCCs), activated PCCs (aPCCs), or rFVIIa reverse the hemostatic alterations induced by rivaroxaban and dabigatran in healthy volunteers?
Population
6 healthy individuals
Comparison
In vitro spiking with prothrombin complex… vs Blood samples treated with rivaroxaban or…
Design
Other
Authors
Loading...
aPCCs may warrant priority for dabigatran reversal; leaves open confirmation in patient bleeding outcomes.
Do prothrombin complex concentrates (PCCs), activated PCCs (aPCCs), or rFVIIa reverse the hemostatic alterations induced by rivaroxaban and dabigatran in healthy volunteers?
Ex vivo testing suggests aPCCs may be the most effective agent for reversing dabigatran-induced hemostatic alterations, while rivaroxaban can be reversed by PCCs, aPCCs, and rFVIIa.
Galán et al. (2012) studied Healthy volunteers (n=6). Prothrombin complex concentrates (PCCs), activated PCCs (aPCCs), and rFVIIa was evaluated on Reversal of alterations in hemostasis (thrombin generation, thromboelastometry, standard coagulation parameters, fibrin deposition). In healthy volunteers, hemostatic alterations induced by rivaroxaban were reversed by PCCs, aPCCs, and rFVIIa, whereas dabigatran effects were only reversed by aPCCs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: